S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Become an Investor in Brooklyn Gin (Ad)pixel
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Become an Investor in Brooklyn Gin (Ad)pixel
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Become an Investor in Brooklyn Gin (Ad)pixel
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Become an Investor in Brooklyn Gin (Ad)pixel
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Become an Investor in Brooklyn Gin (Ad)pixel
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Become an Investor in Brooklyn Gin (Ad)pixel
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Become an Investor in Brooklyn Gin (Ad)pixel
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Become an Investor in Brooklyn Gin (Ad)pixel
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
NASDAQ:REGN

Regeneron Pharmaceuticals - REGN Stock Forecast, Price & News

$736.46
-6.37 (-0.86%)
(As of 01/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$732.50
$749.00
50-Day Range
$680.49
$766.39
52-Week Range
$538.01
$779.00
Volume
467,592 shs
Average Volume
610,643 shs
Market Capitalization
$80.20 billion
P/E Ratio
15.53
Dividend Yield
N/A
Price Target
$786.15

Regeneron Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.65 Rating Score
Upside/​Downside
8.4% Upside
$798.65 Price Target
Short Interest
Healthy
1.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.68
Upright™ Environmental Score
News Sentiment
0.70mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 30 Articles This Week
Insider Trading
Selling Shares
$14.07 M Sold Last Quarter
Proj. Earnings Growth
-3.69%
From $38.24 to $36.83 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

247th out of 1,049 stocks

Pharmaceutical Preparations Industry

119th out of 514 stocks


REGN stock logo

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Stock News Headlines

Four Undervalued Healthcare Stocks for 2023 (REGN)
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.
Regeneron (REGN) Stock Moves -0.86%: What You Should Know
Invest in Brooklyn Gin: Hot craft spirits opportunity
Get in on an award winning company in the fast growing craft spirits marketpixel
Invest in Brooklyn Gin: Hot craft spirits opportunity
Get in on an award winning company in the fast growing craft spirits marketpixel
Regeneron Pharma: CHMP Adopts Positive Opinion For Dupixent
12 Cheap Biotech Stocks To Buy
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Company Calendar

Last Earnings
11/03/2022
Today
1/30/2023
Next Earnings (Confirmed)
2/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
10,368
Year Founded
1988

Price Target and Rating

Average Stock Price Forecast
$798.65
High Stock Price Forecast
$970.00
Low Stock Price Forecast
$625.00
Forecasted Upside/Downside
+6.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.65
Research Coverage
20 Analysts

Profitability

Net Income
$8.08 billion
Pretax Margin
44.04%

Debt

Sales & Book Value

Annual Sales
$16.07 billion
Cash Flow
$80.14 per share
Book Value
$172.92 per share

Miscellaneous

Free Float
99,112,000
Market Cap
$80.20 billion
Optionable
Optionable
Beta
0.22

Social Links


Key Executives

  • Leonard S. SchleiferLeonard S. Schleifer
    Co-President, Chief Executive Officer & Director
  • George Damis YancopoulosGeorge Damis Yancopoulos
    Co-President, Director & Chief Scientific Officer
  • Patrice Gilooly
    Senior VP-Quality Assurance & Operations
  • Robert E. LandryRobert E. Landry
    Chief Financial Officer & Executive VP-Finance
  • Neil StahlNeil Stahl
    Executive VP-Research & Development













REGN Stock - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REGN shares.
View REGN analyst ratings
or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price forecast for 2023?

20 brokerages have issued 1 year price objectives for Regeneron Pharmaceuticals' stock. Their REGN share price forecasts range from $625.00 to $970.00. On average, they predict the company's share price to reach $798.65 in the next year. This suggests a possible upside of 8.4% from the stock's current price.
View analysts price targets for REGN
or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2023?

Regeneron Pharmaceuticals' stock was trading at $721.49 on January 1st, 2023. Since then, REGN shares have increased by 2.1% and is now trading at $736.46.
View the best growth stocks for 2023 here
.

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 3rd 2023.
View our REGN earnings forecast
.

How can I listen to Regeneron Pharmaceuticals' earnings call?

Regeneron Pharmaceuticals will be holding an earnings conference call on Friday, February 3rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its quarterly earnings data on Thursday, November, 3rd. The biopharmaceutical company reported $9.98 earnings per share for the quarter, beating analysts' consensus estimates of $8.55 by $1.43. The biopharmaceutical company had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.79 billion. Regeneron Pharmaceuticals had a net margin of 39.17% and a trailing twelve-month return on equity of 31.16%.

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Sustainable Growth Advisers LP (0.40%), Sumitomo Mitsui Trust Holdings Inc. (0.35%), New York State Common Retirement Fund (0.17%), New York State Teachers Retirement System (0.11%), Assenagon Asset Management S.A. (0.11%) and Pendal Group Ltd (0.11%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends
.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $736.46.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $80.20 billion and generates $16.07 billion in revenue each year. The biopharmaceutical company earns $8.08 billion in net income (profit) each year or $47.43 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

The company employs 10,368 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.

This page (NASDAQ:REGN) was last updated on 1/31/2023 by MarketBeat.com Staff